A Simple Blood Test That Screens for 50 Cancers
How the Galleri® Blood Test May Change Cancer Screening Forever
Imagine being able to check for dozens of cancers with just one blood drawing, including the types that often go undetected until it’s too late, like ovarian, pancreatic, liver, and esophageal cancer.
What is Galleri Test and How It Works
The Galleri test, developed by GRAIL, Inc., is a multi-cancer early detection (MCED) blood test designed to screen for more than 50 different types of cancer from a single blood draw- giving patients and practitioners a head starts on some of the most difficult-to-detect diseases.
The test looks for fragments of cell-free DNA (cfDNA) in the bloodstream, which are shed by cancer cells, and uses methylation signatures and machine-learning algorithms to detect a “cancer signal” and to predict where in the body that signal likely originates.
It is not a diagnostic test (i.e., a positive result does not definitively mean cancer is present, and a negative result does not guarantee absence of cancer).
Why This Matters
Right now, routine screening only exists for a few cancers — like breast, colon, cervical, and (for some people) lung cancer.
Unfortunately, most cancers don’t have a regular test to catch them early.
That’s why diseases such as pancreatic, ovarian, liver, bile duct, and esophageal cancer are often found only after symptoms appear, when they’re already advanced and harder to treat.
The Galleri test aims to fill that gap — to help doctors find cancers that typically go unnoticed until it’s too late.
What Research Shows So Far
Studies on the Galleri test are still ongoing, but early data are promising:
Accuracy (Specificity): Around 99.5%, meaning correctly no signal when no cancer
Overall sensitivity (ability of detecting cancer signal when cancer is present): About 51% overall, but much higher for certain cancers and later stages.
Detection for advanced but hard-to-find cancers:
🩺 Ovarian cancer – 83% overall detection
🩺 Pancreatic cancer – 84% overall
🩺 Liver and bile duct cancer – 93% overall
🩺 Esophageal cancer – 85% overall
🩺 Head and neck cancers – 86% overall
🩺 Lung cancer – 75% overall
🩺 Colorectal cancer – 82% overall
These numbers come from published research and data shared by GRAIL and independent studies.
✳️ The test performs best in detecting later-stage disease, but it’s also showing progress in finding earlier-stage cancers — exactly what researchers are working to improve.
Real-World Evidence: PATHFINDER-2 Study
In a major study called PATHFINDER-2, researchers combined the Galleri test with traditional screenings and found:
A 7x increase in overall cancer detection
Many cancers are found at earlier, more treatable stages
These findings suggest that multi-cancer blood testing could significantly change how we approach prevention — especially for cancers that don’t yet have routine screening.
How to interpret the results
Cancer Signal Detected: Does not mean you have cancer, but it means that further diagnostic evaluation is recommended.
No Cancer Signal Detected: Does not guarantee you are cancer-free; you should continue routine screening and monitoring as recommended by your provider.
The test’s accuracy varies by cancer type and by stage — early-stage disease is harder to detect. For example, many cancers in Stage I are detected less reliably.
Who Should Consider the Galleri Test
The Galleri test is available in the U.S. by prescription.
It’s most often recommended for:
Adults aged 50 and older, or
Younger adults with increased cancer risk (family history, genetic mutations, or environmental exposures).
If you’re proactive about prevention — the type of person who values insight over waiting — this test aligns beautifully with that philosophy.
🌿 Functional medicine is about catching imbalances early. The Galleri test extends that same principle to cancer detection.
Limitations to Keep in Mind
While the promise is exciting, it’s important to stay balanced:
Galleri is not yet FDA-approved for population-wide screening.
Insurance coverage is currently limited (some pilot programs and concierge practices offer it).
It can miss very early cancers or cause anxiety if follow-up testing is required.
Like any new technology, more long-term research is needed to show whether it truly reduces cancer deaths.
Key Takeaways
The Galleri test offers an exciting glimpse into the future of cancer prevention.
It does not replace traditional screenings like mammograms, colonoscopies, Pap tests, or PSA tests. Instead, it’s meant to be a complementary tool — an additional layer of prevention and awareness.
If you have a family history of cancer, unexplained fatigue, inflammation, or just want to take a more comprehensive approach to prevention, talk to your provider about whether the Galleri multi-cancer test is right for you.
Early detection isn’t just about finding cancer — it’s about protecting your future.
References:
AAFP Diagnostic Test Review (2024) – Multi-Cancer Early Detection Blood Tests: Sensitivity and Specificity Summary.
PATHFINDER-2 Clinical Study – Presented at ASCO 2024: Early results on real-world implementation of Galleri testing.
Guardant Health (2024). Shield and multi-cancer early detection program summaries.
ClinicalTrials.gov Identifier: NCT04241796 – PATHFINDER-2 Galleri Study.
GRAIL Press Release. PATHFINDER-2 results demonstrate earlier detection of multiple cancers.
GRAIL, Inc. Galleri Test Performance Data and Clinical Validation. https://www.galleri.com